Braintree, Mass. – October 11, 2026 -- Braintree Laboratories, part of Sebela Pharmaceuticals, reported that its investigational P-CAB tegoprazan delivered statistically significant gains over placebo in both heartburn and regurgitation in the 783-patient Phase 3 TRIUMpH-NERD study. The company describes it as the first P-CAB to show clinical improvement in both hallmark non-erosive reflux disease (NERD) symptoms in a prospective U.S. Phase 3 trial.